Concomitant pregnancy and breast cancer: Options for systemic therapy

Breast Disease

Volumn 23, Issue , 2005, Pages 95-101

  Kelly, Hanna L ^a   Collichio, Frances A ^a   Dees, E Claire ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GADOLINIUM; GLYCOPROTEIN P; LAPATINIB; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TECHNETIUM 99M; TRASTUZUMAB; VASCULOTROPIN A; VINCA ALKALOID; ANTHRACYCLINE;

ADULT; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIRTH DEFECT; BONE MARROW HYPOPLASIA; BRAIN VENTRICLE HEMORRHAGE; BREAST BIOPSY; BREAST CANCER; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; DRUG SAFETY; ECHOMAMMOGRAPHY; ENCEPHALOMALACIA; ENDOMETRITIS; ENTEROCOLITIS; FEMALE; FETUS DEATH; FETUS MALFORMATION; FETUS OUTCOME; HEART DISEASE; HUMAN; HYALINE MEMBRANE DISEASE; INTRAUTERINE GROWTH RETARDATION; JAUNDICE; LEUKEMIA; LEUKOPENIA; LOW BIRTH WEIGHT; LYMPHOMA; METASTASIS; MOUSE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN SEPSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PNEUMONIA; PNEUMOTHORAX; POLYCYTHEMIA; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; RADIATION EXPOSURE; RESPIRATORY DISTRESS SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS ABORTION; STILLBIRTH; TACHYPNEA; TERATOGENESIS; TERATOGENICITY; VESICOURETERAL REFLUX; BREAST TUMOR; DRUG EFFECT; FETUS; MORTALITY; PREGNANCY; REVIEW;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FETUS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 33748109879     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2006-23113     Document Type: Article

References (68)

1. L. Ries, M. Eisner, C. Kosary et al., SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD Based on November 2004 SEER data submission, posted to the SEER web site 2005. 2005. http://seer.cancer.gov/csr/1975_2002/. Accessed.
2. N.M. Antonelli, D.J. Dotters, V.L. Katz et al., Cancer in pregnancy: A review of the literature, Part I. Obstet Gynecol Surv 51 (1996), 125-134.
3. J.I. Sorosky and C.E. Scott-Conner, Breast disease complicating pregnancy, Obstet Gynecol Clin North Am 25 (1998), 353-363.
4. J.C. Woo, T. Yu and T.C. Hurd, Breast cancer in pregnancy: A literature review, Arch Surg 138 (2003), 91-98; discussion 99.
5. A.E. Ring, L.E. Smith, A. Jones et al., Chemotherapy for breast cancer during pregnancy: An 18-year experience from five London teaching hospitals, J Clin Oncol 23 (2005), 4192-4197.
6. R.M. Elledge, D.R. Ciocca, G. Langone et al., Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients, Cancer 71 (1993), 2499-2506.
7. P. Bonnier, S. Romain, J.M. Dilhuydy et al., Influence of pregnancy on the outcome of breast cancer: A case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group, Int J Cancer 72 (1997), 720-727.
8. J.R. Dating, K.E. Malone, D.R. Doody et al., The relation of reproductive factors to mortality from breast cancer, Cancer Epidemiol Biomarkers Prev 11 (2002), 235-241.
9. B.O. Anderson, J.A. Petrek, D.R. Byrd et al., Pregnancy influences breast cancer stage at diagnosis in women 30 years of age and younger, Ann Surg Oncol 3 (1996), 204-211.
10. T. Ishida, T. Yokoe, F. Kasumi et al., Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: Analysis of case-control study in Japan, Jpn J Cancer Res 83 (1992), 1143-1149.
11. W. Reed, E. Hannisdal, E. Skovlund et al., Pregnancy and breast cancer: a population-based study, Virchows Arch 443 (2003), 44-50.
12. D. Zemlickis, M. Lishner, P. Degendorfer et al., Maternal and fetal outcome after breast cancer in pregnancy, Am J Obstet Gynecol 166 (1992), 781-787.
13. A.H. Nicklas and M.E. Baker, Imaging strategies in the pregnant cancer patient, Semin Oncol 27 (2000), 623-632.
14. L. Liberman, C.S. Giess, D.D. Dershaw et al., Imaging of pregnancy-associated breast cancer, Radiology 191 (1994), 245-248.
15. B.Y. Ahn, H.H. Kim, W.K. Moon et al., Pregnancy- and lactation-associated breast cancer: Mammographic and sonographic findings, J Ultrasound Med 22 (2003), 491-497; quiz 498-499.
16. S.J. Adelstein, Administered radionuclides in pregnancy, Teratology 59 (1999), 236-239.
17. I. Maghfoor and D.C. Doll, Chemotherapy in Pregnancy, in: The Chemotherapy Source Book (3rd ed), M.C. Perry, eds, Philadelphia, Lippincott, Williams & Wilkins, 2001, pp. 537-546.
18. E. Cardonick and A. Iacobucci, Use of chemotherapy during human pregnancy, Lancet Oncol 5 (2004), 283-291.
19. T.E. Buekers and T.A. Lallas, Chemotherapy in pregnancy, Obstet Gynecol Clin North Am 25 (1998), 323-329.
20. U. Ebert, H. Loffler and W. Kirch, Cytotoxic therapy and pregnancy, Pharmacol Ther 74 (1997), 207-220.
21. D. Zemlickis, M. Lishner, P. Degendorfer et al., Fetal outcome after in utero exposure to cancer chemotherapy, Arch Intern Med 152 (1992), 573-576.
22. R.M. Peres, M.T. Sanseverino, J.L. Guimaraes et al., Assessment of fetal risk associated with exposure to cancer chemotherapy during pregnancy: A multicenter study, Braz J Med Biol Res 34 (2001), 1551-1559.
23. P.L. Giacalone, F. Laffargue and P. Benos, Chemotherapy for breast carcinoma during pregnancy: A French national survey, Cancer 86 (1999), 2266-2272.
24. K. Gwyn and R.L. Theriault, Breast cancer during pregnancy and lactation, 2005. Accessed 2005, August 29.
25. N. Germann, F. Goffinet and F. Goldwasser, Anthracyclines during pregnancy: Embryo-fetal outcome in 160 patients, Ann Oncol 15 (2004), 146-150.
26. D.L. Berry, R.L. Theriault, F.A. Holmes et al., Management of breast cancer during pregnancy using a standardized protocol, J Clin Oncol 17 (1999), 855-861.
27. F. Peccatori, G. Martinelli, O. Gentilini et al., Chemotherapy during pregnancy: What is really safe? Lancet Oncol 5 (2004), 398.
28. C. Andreadis, M. Charalampidou, N. Diamantopoulos et al., Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer, Gynecol Oncol 95 (2004), 252-255.
29. J.J. Turchi and C. Villasis, Anthracyclines in the treatment of malignancy in pregnancy, Cancer 61 (1988), 435-440.
30. M. Meyer-Wittkopf, H. Barth, G. Emons et al., Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: Case report and review of the literature, Ultrasound Obstet Gynecol 18 (2001), 62-66.
31. A. Gadducci, S. Cosio, A. Fanucchi et al., Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: Case report and review of the literature, Anticancer Res 23 (2003), 5225-5229.
32. P.V. Ginopoulos, G.D. Michail and G.S. Kourounis, Pregnancy associated breast cancer: A case report, Eur J Gynaecol Oncol 25 (2004), 261-263.
33. F. Goldwasser, J.L. Pico, J. Cerrina et al., Successful chemotherapy including epirubicin in a pregnant non-Hodgkin's lymphoma patient, Leak Lymphoma 20 (1995), 173-176.
34. T. Muller, J. Hofmann and T. Steck, Eclampsia after polychemotherapy for nodal-positive breast cancer during pregnancy, Eur J Obstet Gynecol Reprod Biol 67 (1996), 197-198.
35. C. Stewart and M. Ratain, Topoisomerase interactive agents, in: Cancer, Principles and Practice of Oncology (6th ed), V.T. Devita, S. Hellman and S.A. Rosenberg, eds, Philadelphia, Lippincott Williams & Wilkins, 2001, pp. 415-430.
36. A.M. Gonzalez-Angulo, R.S. Walters, R.J. Carpenter, Jr. et al., Pactitaxel chemotherapy in a pregnant patient with bilateral breast cancer, Clin Breast Cancer 5 (2004), 317-319.
37. M. De Santis, A. Lucchese, S. De Carolis et al., Metastatic breast cancer in pregnancy: First case of chemotherapy with docetaxel, Eur J Cancer Care (Engl) 9 (2000), 235-237.
38. L.E. Mendez, A. Mueller, E. Salom et al., Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer, Obstet Gynecol 102 (2003), 1200-1202.
39. A.K. Sood, M.S. Shahin and J.I. Sorosky, Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy, Gynecol Oncol 83 (2001), 599-600.
40. J.V. Glantz, Reproductive toxicology of alkylating agents, Obstet Gynecol Surv 49 (1994), 709-715.
41. L. Say, R. Kulier, M. Gulmezoglu et al., Medical versus surgical methods for first trimester termination of pregnancy, Cochrane Database Syst Rev (2005), CD003037.
42. K. Tewari, R.G. Bonebrake, T. Asrat et al., Ambiguous genitalia in infant exposed to tamoxifen in utero, Lancet 350 (1997), 183.
43. S.L. Cullins, G. Pridjian and C.M. Sutherland, Goldenhar's syndrome associated with tamoxifen given to the mother during gestation, Jama 271 (1994), 1905-1906.
44. R.J. Isaacs, W. Hunter and K. Clark, Tamoxifen as systemic treatment of advanced breast cancer during pregnancy-case report and literature review, Gynecol Oncol 80 (2001), 405-408.
45. E.H. Romond, E.A. Perez, J. Bryant et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med 353 (2005), 1673-1684.
46. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med 353 (2005), 1659-1672.
47. P.J. Miettinen, J.E. Berger, J. Meneses et al., Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor, Nature 376 (1995), 337-341.
48. P.J. Miettinen, J.R. Chin, L. Shum et al., Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure, Nat Genet 22 (1999), 69-73.
49. S. Yoshimura, H. Masuzaki, K. Miura et al., Effect of epidermal growth factor on lung growth in experimental fetal pulmonary hypoplasia, Early Hum Dev 57 (2000), 61-69.
50. R.C. Burrows, D. Wancio, P. Levitt et al., Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex, Neuron 19 (1997), 251-267.
51. K.F. Lee, H. Simon, H. Chen et al., Requirement for neuregulin receptor erbB2 in neural and cardiac development, Nature 378 (1995), 394-398.
52. W.J. Watson, Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios, Obstet Gynecol 105 (2005), 642-643.
53. N. Ferrara, Vascular endothelial growth factor: Basic science and clinical progress, Endocr Rev 25 (2004), 581-611.
54. K. Miller, E2100 Sudy. Scientific session on monoclonal antibody therapy in breast cancer, Orlando, FL: Annual meeting of the American Society of Clinical Oncology. 2005. http://www.asco.org/ac/ 1,1003,_12-002511-00_18-0034-00_19-005814-00_21-001,00.asp. Accessed 2005, August 29.
55. A.M. Sharkey, R. Catalano, A. Evans et al., Novel antiangiogenic agents for use in contraception, Contraception 71 (2005), 263-271.
56. N. Klauber, R.M. Rohan, E. Flynn et al., Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470, Nat Med 3 (1997), 443-446.
57. A. Aviles and N. Neri, Hematological malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero, Clin Lymphoma 2 (2001), 173-177.
58. D. Zemlickis, M. Lishner, R. Erlich et al., Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide, Teratog Carcinog Mutagen 13 (1993), 139-143.
59. J.W. Smit, M.T. Huisman, O. van Tellingen et al., Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure, J Clin Invest 104 (1999), 1441-1447.
60. E.M. Leslie, R.G. Deeley and S.P. Cole, Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicol Appl Pharmacol 204 (2005), 216-237.
61. B.A. Mueller, M.S. Simon, D. Deapen et al., Childbearing and survival after breast carcinoma in young women, Cancer 98 (2003), 1131-1140.
62. E.M. Ibrahim, A.A. Ezzat, A. Baloush et al., Pregnancy-associated breast cancer: A case-control study in a young population with a high-fertility rate, Med Oncol 17 (2000), 293-300.
63. J. Zhang, G. Liu, J. Wu et al., Pregnancy-associated breast cancer: A case control and long-term follow-up study in China, J Exp Clin Cancer Res 22 (2003), 23-27.
64. A. Ezzat, M.A. Raja, J. Berry et al., Impact of pregnancy on non-metastatic breast cancer: A case control study, Clin Oncol (R Coll Radiol) 8 (1996), 367-370.
65. J.A. Petrek, R. Dukoff and A. Rogatko, Prognosis of pregnancy-associated breast cancer, Cancer 67 (1991), 869-872.
66. V.F. Guinee, H. Olsson, T. Moller et al., Effect of pregnancy on prognosis for young women with breast cancer, Lancet 343 (1994), 1587-1589.
67. S. Tretli, G. Kvalheim, S. Thoresen et al., Survival of breast cancer patients diagnosed during pregnancy or lactation, Br J Cancer 58 (1988), 382-384.
68. A.E. Lethaby, M.A. O'Neill, B.H. Mason et al., Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group, Int J Cancer 67 (1996), 751-755.